NVIDIA and Lilly Team Up to Create an AI Lab to Transform How New Drugs are Discovered Using AI Technology

Jan 14, 2026- by CMI| Category : Pharmaceutical1 min read
NVIDIA and Lilly Team Up to Create an AI Lab to Transform How New Drugs are Discovered Using AI Technology

NVIDIA and Eli Lilly have announced a new partnership to make an AI lab focused on solving major challenges in the pharmaceutical industry using artificial intelligence (AI). The lab will combine Lilly's expertise in medicine with NVIDIA's AI technology and computing power.

The two companies plan to invest up to USD 1 billion over the next five years to support the lab, which will be located in the San Francisco Bay Area. The aim is to adopt AI to fasten the development of new medicines by operating along with prominent scientists as well as AI engineers from both companies.

Key Focus Areas:

  • AI for Drug Discovery: The lab will make a consistent system that links wet labs (biological experiments) with dry labs (computational analysis). This will bring AI to assist in experiments 24/7, aiding scientists in improving their work through constant feedback.
  • Advanced AI Models: The teams will use NVIDIA's BioNeMo platform to build powerful AI models for biology and chemistry, speeding up drug development as well as optimizing molecules.
  • AI in Manufacturing: In addition to drug discovery, the lab will explore using AI to improve manufacturing, clinical trials, and supply chains. For example, AI and robotics will help Lilly improve manufacturing capacity and ensure reliable supply chains.
  • Digital Twins: Lilly will use NVIDIA's Omniverse as well as RTX PRO Servers to create digital twins of its manufacturing lines. These virtual models will help test and optimize production processes before making real-world changes.

The lab will open in South San Francisco later this year, bringing together Lilly's scientists and NVIDIA's AI engineers to push the boundaries of biomedical discovery.

Executive Statement

According to Jensen Huang, founder and CEO of NVIDIA, AI is transforming every industry, and its most profound impact will be in life sciences. NVIDIA and Lilly are bringing together the best of their industries to invent a new blueprint for drug discovery, one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.

Share this story

About the author

Ravina Pandya

is a seasoned content writer with over 3.5 years of hands-on experience across various writing formats, including news articles, blog posts, press releases, and informational content. Her expertise lies in producing high-quality, informative content tailored to meet the specific needs of diverse industries, such as Biotechnology, Clinical Diagnostic, Healthcare IT, advanced material, and Medical Devices. She has a deep understanding of how to craft engaging narratives that align with industry trends, helping businesses enhance their online presence and communicate effectively with their audiences.

What sets Ravina apart is her keen eye for detail and her passion for storytelling. She approaches every piece of content with the intent to make it not just informative but also impactful, ensuring that it resonates with the audience on a deeper level. With a reputation for producing timely and relevant articles, she has made significant contributions to the field by helping companies effectively communicate their brand message through engaging, clear, and creative writing. As an advocate for clarity in communication, she continues to explore new ways of refining her craft while remaining at the forefront of content trends.